Description
This antibody is a biosimilar generically called Oxelumab (CAS 1186098-83-8) and originally developed by Genentech. The humanized anti-TNFSF4 antibody was generated by immunizing HCo12 human IgG transgenic mice with alternating administration of recombinant human OX40L and human OX40L-expressing cells. The antibody was recombinantly generated based on the sequence of the original humanized anti-OX40L antibody. Oxelumab is a OX40 ligand blocker designed for the prevention of allergen-induced airway inflammation in adults with mild asthma. Potentially other application areas are transplantation and autoimmunity research or protection against inflammation-driven fibrosis. Recognizes human OX40L. Species cross-reactivity: Human. Clone: R4930. Isotype: Human IgG1kappa. Applications: FACS, FUNC, FUNC (Blocking). Host: CHO cells. Liquid. In PBS. OX40L is a membrane-expressed cytokine that belongs to the TNF ligand family. It acts as costimulator through interaction with its ligand OX40 on T cells, stimulating T cell activation, proliferation and cytokine production. OX40L is expressed on antigen presenting cells including B cells, dendritic cells, mast cells and endothelium.
Target
OX40L
Target Alias Names
CD252, CD134L, OX40 Ligand, TNFSF4, Tumor Necrosis Factor Superfamily Member 4, TAX Transcriptionally-activated Glycoprotein 1, TXGP1, gp34
Isotype/Mimetic
Human IgG1kappa
Animal-Derived Biomaterials Used
None
Sequence Available
Yes
Original Discovery Method
Animal-derived from hybridomas excluding ascites
Original Discovery Information Provided On Datasheet
No
Antibody/Binder Origins
Animal-dependent discovery (in vitro display, OR immunisation pre-2020), In vitro recombinant expression